Cancer-testis antigens (CTAs) are considered as unique and promising cancer biomarkers
and targets for cancer therapy. CTAs are multifunctional protein group with specific …

Cancer/testis antigens (CTAs) are named based on their expression pattern that is restricted
in a number of normal and abnormal tissues. Tumor cells frequently express antigens whose …

Cancer-testis antigens (CTA) are tumor antigens, present in the germ cells of testes, ovaries
and trophoblasts, which undergo deregulated expression in the tumor and malignant cells …

Increasing evidence shows that numerous cancer-testis antigens (CTAs) are uniquely
overexpressed in various types of cancer and most CTAs are oncogenic. Overexpression of …

Cancer–testis (CT) antigens are potential targets for cancer immunotherapy because of their
restricted expression in immune-privileged germ cells and various malignancies. Current …

Cancer/testis antigens (CTAs) are a group of tumor antigens expressed in numerous cancer
tissues, as well as in the testis and placental tissues. There are over 200 CTAs supported by …

Recent developments have set the stage for immunotherapy as a supplement to
conventional cancer treatment. Consequently, a significant effort is required to further …

Tumour-specific antigens have been an area of interest in cancer therapy since their
discovery in the middle of the 20th century. In the era of immune-based cancer therapeutics …

In the multistep process of cancer development, the concept that cancer stem cells are
derived from normal stem cells that have gradually accumulated various genetic and …

Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed
diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor …